Open access · CC-BY
via OpenAlex
Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: implications in aging and Alzheimer’s disease
Sultan Darvesh, Meghan K. Cash, Katrina L. Forrestall, Hillary Maillet, Dane C. Sands
Aging · 2025 · ▲ 4 citations
Abstract
Cellular senescence(definition) is a hallmark of aging and the age-related condition, Alzheimer’s disease (AD). How senescence contributes to cholinergic and neuropathologic changes in AD remains uncertain. Furthermore, little is known about the relationship between senescence and cholinesterases (ChEs). Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are important in neurotransmission, cell cycle regulation, and AD amyloid-β (Aβ) pathology. Senolytic agents have shown therapeutic promise in AD models. Therefore, we evaluated in vitro and in silico activity of senolytics(definition), dasatinib (1), nintedanib (2), fisetin (3), quercetin (4), GW2580 (5), and nootropic, meclofenoxate hydrochloride (6), toward AChE and BChE. As ChEs associated with AD pathology have altered biochemical properties, we also evaluated agents 1-6 in AD brain tissues. Enzyme kinetics showed agents 1, 3, 4, and 6 inhibited both ChEs, while 2 and 5 inhibited only AChE. Histochemistry showed inhibition of Aβ plaque-associated ChEs (1 and 2: both ChEs; 5: BChE; 6: AChE), but not normal neural-associated ChEs. Modeling studies showed 1-6 interacted with the same five binding locations of both ChEs, some of which may be allosteric sites. These agents may exert their beneficial effects, in part, by inhibiting ChEs associated with AD pathology and provide new avenues for development of next-generation inhibitors targeting pathology-associated ChEs.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.18632/aging.206227
- Canonical
- link ↗
- Fetched
- 2026-11-12 MST
Cite this
APA
Darvesh, S., Cash, M.K., Forrestall, K.L., Maillet, H., & Sands, D.C. (2025). Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: implications in aging and Alzheimer’s disease. <em>Aging</em>. https://doi.org/10.18632/aging.206227
Vancouver
Darvesh S, Cash MK, Forrestall KL, Maillet H, Sands DC. Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: implications in aging and Alzheimer’s disease. Aging. 2025. doi:10.18632/aging.206227.
BibTeX
@article{sultan2025Differ,
title = {Differential senolytic inhibition of normal versus Aβ-associated cholinesterases: implications in aging and Alzheimer’s disease},
author = {Sultan Darvesh and Meghan K. Cash and Katrina L. Forrestall and Hillary Maillet and Dane C. Sands},
journal = {Aging},
year = {2025},
doi = {10.18632/aging.206227},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging Cell 2019
Open access · CC-BY
Astrocyte senescence: Evidence and significance
Cancer Management and Research 2020
Open access · OA
The Dynamic Process and Its Dual Effects on Tumors of Therapy-Induced Senescence
2026
Open access · OA
Senolytic therapy in Alzheimer’s disease: clinical evidence and biomarkers
Journal of Orthopaedic Translation 2024
Open access · CC-BY
Mechanisms and therapeutic strategies for senescence-associated secretory phenotype in the intervertebral disc degeneration microenvironment
International journal of molecular sciences 2026
Open access · OA
Reprogramming the Aging Type H Vascular Niche via Myeloid Angiogenic Cell-Derived Extracellular Vesicles: Mechanisms, Engineering Strategies, and Translational Perspectives.
I P Pavlov Russian Medical Biological Herald 2025
Citation only